<?xml version="1.0" encoding="UTF-8"?>
<abstract id="16793810">
  <title>
    <s id="0" section="title">
      Effect of
      <group id="0">perioperative  beta  blockade</group>
      in patients with diabetes undergoing major non - cardiac surgery : randomised placebo controlled , blinded multicentre trial .
    </s>
  </title>
  <annotated>
    <s id="4" section="setting">University anaesthesia and surgical centres and 1 coordinating centre .</s>
    <s id="5" section="participants">
      <ps>921</ps>
      patients aged &gt; 39 scheduled for major non - cardiac surgery .
    </s>
    <s id="6" section="interventions">
      <group id="0">
        100  mg
        <short>metoprolol</short>
        controlled  and  extended  release
      </group>
      or
      <group id="1">placebo</group>
      administered from the day before surgery to a maximum of 8 perioperative days .
    </s>
    <s id="10" section="results">
      <group id="0">Metoprolol</group>
      significantly reduced the
      <outcome id="7">mean  heart  rate</outcome>
      by 11 % ( 95 % confidence interval 9 % to 13 % ) and
      <outcome id="8">mean  blood  pressure</outcome>
      by 3 % ( 1 % to 5 % ) .
    </s>
    <s id="11" section="results">
      The
      <outcome id="0" type="bad">primary  outcome</outcome>
      occurred in
      <on group="0" outcome="0">99</on>
      of
      <gs group="0">462</gs>
      patients in the
      <group id="0">metoprolol  group</group>
      ( 21 % ) and
      <on group="1" outcome="0">93</on>
      of
      <gs group="1">459</gs>
      patients in the
      <group id="1">placebo  group</group>
      ( 20 % ) ( hazard ratio 1.06 , 0.80 to 1.41 ) during a median follow - up of
      <time id="0">18  months</time>
      ( range 6-30 ) .
    </s>
    <s id="12" section="results">
      <outcome id="1" type="bad">All  cause  mortality</outcome>
      was 16 % (
      <on group="0" outcome="1">74</on>
      /
      <gs group="0">462</gs>
      ) in the
      <group id="0">metoprolol  group</group>
      and 16 % (
      <on group="1" outcome="1">72</on>
      /
      <gs group="1">459</gs>
      ) in the
      <group id="1">placebo  group</group>
      ( 1.03 , 0.74 to 1.42 ) .
    </s>
  </annotated>
  <fulltext>Effect of perioperative beta blockade in patients with diabetes undergoing major non - cardiac surgery : randomised placebo controlled , blinded multicentre trial . To evaluate the long term effects of perioperative beta blockade on mortality and cardiac morbidity in patients with diabetes undergoing major non - cardiac surgery . Randomised placebo controlled and blinded multicentre trial . Analyses were by intention to treat . University anaesthesia and surgical centres and 1 coordinating centre . 921 patients aged &gt; 39 scheduled for major non - cardiac surgery . 100 mg metoprolol controlled and extended release or placebo administered from the day before surgery to a maximum of 8 perioperative days . The composite primary outcome measure was time to all cause mortality , acute myocardial infarction , unstable angina , or congestive heart failure . Secondary outcome measures were time to all cause mortality , cardiac mortality , and non - fatal cardiac morbidity . Mean duration of intervention was 4.6 days in the metoprolol group and 4.9 days in the placebo group . Metoprolol significantly reduced the mean heart rate by 11 % ( 95 % confidence interval 9 % to 13 % ) and mean blood pressure by 3 % ( 1 % to 5 % ) . The primary outcome occurred in 99 of 462 patients in the metoprolol group ( 21 % ) and 93 of 459 patients in the placebo group ( 20 % ) ( hazard ratio 1.06 , 0.80 to 1.41 ) during a median follow - up of 18 months ( range 6-30 ) . All cause mortality was 16 % ( 74 / 462 ) in the metoprolol group and 16 % ( 72 / 459 ) in the placebo group ( 1.03 , 0.74 to 1.42 ) . The difference in risk for the proportion of patients with serious adverse events was 2.4 % ( - 0.8 % to 5.6 % ) . Perioperative metoprolol did not significantly affect mortality and cardiac morbidity in these patients with diabetes . Confidence intervals , however , were wide , and the issue needs reassessment . Current Controlled Trials ISRCTN58485613 .</fulltext>
  <ignored>
    <s id="1" section="objectives">
      To evaluate the long term effects of
      <group id="0">perioperative  beta  blockade</group>
      on
      <outcome id="5">mortality</outcome>
      and
      <outcome id="6">cardiac  morbidity</outcome>
      in patients with diabetes undergoing major non - cardiac surgery .
    </s>
    <s id="2" section="design">Randomised placebo controlled and blinded multicentre trial .</s>
    <s id="3" section="design">Analyses were by intention to treat .</s>
    <s id="7" section="main_outcome_measures">
      The composite primary outcome measure was
      <outcome id="0" type="bad">time  to  all  cause  mortality  ,  acute  myocardial  infarction  ,  unstable  angina  ,  or  congestive  heart  failure</outcome>
      .
    </s>
    <s id="8" section="main_outcome_measures">
      Secondary outcome measures were
      <outcome id="1" type="bad">time  to  all  cause  mortality</outcome>
      ,
      <outcome id="5">cardiac  mortality</outcome>
      , and
      <outcome id="6">non  -  fatal  cardiac  morbidity</outcome>
      .
    </s>
    <s id="9" section="results">
      Mean duration of intervention was 4.6 days in the
      <group id="0">metoprolol  group</group>
      and 4.9 days in the
      <group id="1">placebo  group</group>
      .
    </s>
    <s id="13" section="results">
      The difference in risk for the proportion of patients with
      <outcome id="10">serious  adverse  events</outcome>
      was 2.4 % ( - 0.8 % to 5.6 % ) .
    </s>
    <s id="14" section="conclusions">
      <group id="0">Perioperative  metoprolol</group>
      did not significantly affect
      <outcome id="5">mortality</outcome>
      and
      <outcome id="6">cardiac  morbidity</outcome>
      in these patients with diabetes .
    </s>
    <s id="15" section="conclusions">Confidence intervals , however , were wide , and the issue needs reassessment .</s>
    <s id="16" section="trial_registration">Current Controlled Trials ISRCTN58485613 .</s>
  </ignored>
</abstract>

